Cargando…

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic

BACKGROUND: Long-Acting cabotegravir/rilpivirine (LA-CAB/RPV) is the first FDA-approved, complete, long-acting injectable antiretroviral therapy (ART) regimen. In clinical trials, LA-CAB/RPV has proven to be highly effective in maintaining virologic suppression in people living with HIV (PLWH) with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez, Sarah, Petersen, Elizabeth, Huhn, Gregory
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677117/ http://dx.doi.org/10.1093/ofid/ofad500.1434

Ejemplares similares

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
por: Sension, Michael G, et al.
Publicado: (2022)

1615. Efficacy of Long-Acting Cabotegravir and Rilpivirine in a Diverse Group of Patients in a Real-World Setting
por: Yared, Nicholas F, et al.
Publicado: (2023)

1028. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in People with HIV with Detectable Viral Loads at Initiation: Findings from the OPERA(®) Cohort
por: Hsu, Ricky K, et al.
Publicado: (2023)

1592. Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine Among People with HIV with Detectable Viral Loads at Initiation: Trio Cohort Study
por: Elion, Rick A, et al.
Publicado: (2023)

1591. Real-world experiences and outcomes implementing long-acting cabotegravir/rilpivirine at a Ryan White HIV/AIDS Program (RWHAP)-funded clinic in South Florida
por: Montalvo, Sheila, et al.
Publicado: (2023)

1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA(®) Cohort
por: Sension, Michael, et al.
Publicado: (2023)

1027. At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implementation Science Trial
por: Williams, Jamila K, et al.
Publicado: (2023)

1589. Real-World Outcomes with Cabotegravir/Rilpivirine: Does Duration of Pre-treatment Viral Suppression Matter?
por: Mesa, Daniel, et al.
Publicado: (2023)

1607. Clinical Outcomes at Month 6 after Initiation of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in an Observational Real-World Study (BEYOND)
por: Sinclair, Gary I, et al.
Publicado: (2023)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND)
por: Dandachi, Dima, et al.
Publicado: (2023)

885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials
por: Patel, Parul, et al.
Publicado: (2021)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results
por: D’Amico, Ronald, et al.
Publicado: (2021)

1586. Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race
por: Patel, Parul, et al.
Publicado: (2022)

877. North American Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes
por: Taiwo, Babafemi O, et al.
Publicado: (2021)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

1024. Real-world Adherence and Persistence with Long-Acting Cabotegravir Plus Rilpivirine (CAB+RPV LA) Compared to Oral Antiretroviral Therapy (ART) Among People with HIV (PWH) in the US: The ABOVE Study
por: Garris, Cindy, et al.
Publicado: (2023)

1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results
por: Chounta, Vasiliki, et al.
Publicado: (2020)

887. Implementation of Long-acting Injectable Cabotegravir/Rilpivirine for HIV-1 Treatment at a Ryan White-funded Clinic in the U.S. South
por: Collins, Lauren F, et al.
Publicado: (2021)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
por: Cutrell, Amy G., et al.
Publicado: (2021)

Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
por: Pintado, Claire, et al.
Publicado: (2020)

1594. Outcomes in Patients Receiving Long-Acting Cabotegravir-Rilpivirine in a Community, Infusion Center-Based Administration Model in Columbus, Ohio
por: Nielsen, Natalie, et al.
Publicado: (2023)

1562. Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB)
por: Ayala, Alvaro, et al.
Publicado: (2023)

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
por: Patel, Parul, et al.
Publicado: (2019)

884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
por: Teichner, Paula, et al.
Publicado: (2019)

Safety and efficacy of long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection: a systematic review and meta-analysis protocol
por: Wu, Yuan-ni, et al.
Publicado: (2022)

1588. Weight Change among People Living with HIV who switch from Oral Antiviral Therapy to Long Acting Injectable Cabotegravir/Rilpivirine in a University-Based Clinic
por: McNaboe, Lukas, et al.
Publicado: (2023)

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
por: Letendre, Scott L, et al.
Publicado: (2020)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

Injectable Long-Acting Cabotegravir–Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start
por: Pinto, Rogério M., et al.
Publicado: (2023)

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
por: Thoueille, Paul, et al.
Publicado: (2022)

875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants
por: Snedecor, Sonya J, et al.
Publicado: (2021)

1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies
por: Teichner, Paula, et al.
Publicado: (2020)

Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
por: Swindells, Susan, et al.
Publicado: (2022)

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
por: Moreno, Santiago, et al.
Publicado: (2023)

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
por: Murray, Miranda, et al.
Publicado: (2020)

Gynoid Fat Distribution and Adipocyte Trapping May Explain Virological Failure With Intramuscular Long-Acting Cabotegravir and Rilpivirine
por: de Malliard, Isabelle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fsq02thqgffisoft2q2oc2m7ir